Evidence map›Paper›PMID 33554389›Full record

ArticleEuropean journal of cancer care2021

Cancer care near the end-of-life in Austria: A retrospective data analysis.

Martin Robausch, Nicole Grössmann, Claudia Wild

Open access · hybridAbstract read
In one paragraph

Article in European journal of cancer care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Anticancer therapy at end-of-life: A retrospective cohort study.Acta oncologica (Stockholm, Sweden) · 2024
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Martin RobauschAustrian Institute for Health Technology Assessment (AIHTA), Vienna, Austria.
Nicole GrössmannAustrian Institute for Health Technology Assessment (AIHTA), Vienna, Austria.ORCID https://orcid.org/0000-0003-4395-4667
Claudia WildAustrian Institute for Health Technology Assessment (AIHTA), Vienna, Austria.
Austrian Institute for Health Technology Assessment GmbH · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSince end-of-life care (EOL) is an internationally accepted indicator for the quality of oncological care we aimed to investigate the current EOL care situation for Austrian cancer patients especially concerning the place of death cancer treatment hospitalisation near death and palliative care.

methodsA retrospective data analysis was carried out based on Austrian routine inpatient data of the years 2012 to 2016. Data including the date of death of adult patients with a main hospital discharge diagnosis of a neoplasm were included. All analyses were source-related and based on the place of residence.

resultsIn total 80818 cancer patients have died between 2012 and 2016 of whom 53.4% died in the inpatient setting. Palliative care at the EOL (last hospitalisation) was present in 12.9% of patients whereby more than 50% were admitted two to 14 days before death. Considering cancer treatment at the EOL (30 days before death) 6.9% of cancer patients have received chemotherapy 1.7% radiation therapy and 0.75% were treated with a monoclonal antibody.

conclusionIn international comparison Austria appears to do well on quality indicators concerning ICU-admission and chemotherapy treatment average on hospital death and poorly on hospital admissions and timely referral for palliative care.

Indexed as

NeoplasmsTerminal CareAdultAustriaData AnalysisDeathHumansPalliative CareRetrospective Studiesaggressive treatmentend-of-Life careoncologyquality indicatorsquality of cancer caresystemic cancer care

Identifiers

PMID33554389
PMCPMC8365662
OpenAlexW3127262279

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.